# EDGAR Filing Document

**Accession Number:** 0000872589
**File Stem:** 0001104659-25-060637
**Filing Date:** 2025-6
**Character Count:** 7860
**Document Hash:** baa08280536b65171bbc573f583e8333
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-060637.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001104659-25-060637

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REGENERON PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000872589
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 133444607
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19034
- **FILM NUMBER:** 251057040

**BUSINESS ADDRESS:**
- **STREET 1:** 777 OLD SAW MILL RIVER ROAD
- **CITY:** TARRYTOWN
- **STATE:** NY
- **ZIP:** 10591
- **BUSINESS PHONE:** 9148477000

**MAIL ADDRESS:**
- **STREET 1:** 777 OLD SAW MILL RIVER ROAD
- **CITY:** TARRYTOWN
- **STATE:** NY
- **ZIP:** 10591

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REGENERON PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 18, 2025 (June 13, 2025)**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**(State or other jurisdiction of incorporation)**

---

| | |
|:---|:---|
| **000-19034** | **13-3444607** |
| **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)**<br>|
| **777 Old Saw Mill River Road, Tarrytown, New York** | **10591-6707** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (914) 847-7000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Trading Symbol(s) | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common Stock – par value $0.001 per share | &nbsp;&nbsp;REGN | &nbsp;&nbsp;NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

At the 2025 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. ("<u>Regeneron</u>" or the "<u>Company</u>") held on June 13, 2025, Regeneron's shareholders voted on the matters set forth below.

**Proposal 1 – Election of Directors** 

The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominee** | **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| Bonnie L. Bassler, Ph.D. | 87348630 | 18594454 | 51195 | 5601648 |
| Michael S. Brown, M.D. | 77025558 | 28913874 | 54847 | 5601648 |
| Leonard S. Schleifer, M.D., Ph.D. | 99271439 | 6672701 | 50139 | 5601648 |
| George D. Yancopoulos, M.D., Ph.D. | 101367161 | 4089290 | 537828 | 5601648 |

---

**Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm** 

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved based upon the following votes:

For: 105,462,255 <br> Against: 6,078,716 <br> Abstain: 54,956

**Proposal 3 – Advisory Vote on Executive Compensation** 

The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 29, 2025 was approved based upon the following votes:

---

| | |
|:---|:---|
| For: | 98781758 |
| Against: | 7100590 |
| Abstain: | 111931 |
| Broker Non-Votes: | 5601648 |

---

**Proposal 4 – Amendment to the Company's Certificate of Incorporation to Declassify the Board of Directors**

The proposal to amend the Company's Certificate of Incorporation to declassify the board of directors was approved based upon the following votes:

---

| | |
|:---|:---|
| For: | 85711231 |
| Against: | 20226748 |
| Abstain: | 56300 |
| Broker Non-Votes: | 5601648 |

---

**Proposal 5 – Two Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements**

*Proposal 5(a) – Amendment to Article IV, Section 2(e)(8) of the Company's Certificate of Incorporation Relating to the Mandatory Conversion of Class A Stock to Common Stock upon a Transfer* 

The proposal to amend Article IV, Section 2(e)(8) of the Company's Certificate of Incorporation, which required the affirmative vote of holders of the majority of the shares of Class A stock, par value $0.001 per share ("<u>Class A stock</u>"), outstanding, and the affirmative vote of holders of two-thirds of the shares of common stock, par value $0.001 per share ("<u>common stock</u>"), outstanding, each voting separately as a class, was not approved based upon the following votes:

**<u>Class A Stock</u>**

For: 0 <br> Against: 18,081,400 <br> Abstain: 0

**<u>Common Stock</u>**

---

| | |
|:---|:---|
| For: | 85490681 |
| Against: | 2279384 |
| Abstain: | 142814 |
| Broker Non-Votes: | 5601648 |

---

*Proposal 5(b) – Amendment to Article VI of the Company's Certificate of Incorporation Relating to the Removal of Directors for Cause*

The proposal to amend Article VI of the Company's Certificate of Incorporation, which required the affirmative vote of at least 80% of the outstanding shares of all classes of capital stock entitled to vote in the election of directors, with holders of common stock and Class A stock voting together as a single class and holders of Class A stock entitled to ten votes per share, was not approved based upon the following votes:

---

| | |
|:---|:---|
| For: | 85490182 |
| Against: | 20360243 |
| Abstain: | 143854 |
| Broker Non-Votes: | 5601648 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| |
|:---|
| **REGENERON PHARMACEUTICALS, INC.** |
| /s/ Joseph J. LaRosa |
| Joseph J. LaRosa |
| Executive Vice President, General Counsel and Secretary |

---

Date: June 18, 2025